These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19264351)

  • 61. A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
    Reyners AKL; de Munck L; Erdkamp FLG; Smit WM; Hoekman K; Lalisang RI; de Graaf H; Wymenga ANM; Polee M; Hollema H; van Vugt MATM; Schaapveld M; Willemse PHB;
    Ann Oncol; 2012 Nov; 23(11):2896-2902. PubMed ID: 22689176
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma.
    Brown JV; Micha JP; Rettenmaier MA; Abaid LN; Lopez KL; Goldstein BH
    Int J Gynecol Cancer; 2010 Oct; 20(7):1132-6. PubMed ID: 21495214
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
    Coleman RL; Duska LR; Ramirez PT; Heymach JV; Kamat AA; Modesitt SC; Schmeler KM; Iyer RB; Garcia ME; Miller DL; Jackson EF; Ng CS; Kundra V; Jaffe R; Sood AK
    Lancet Oncol; 2011 Nov; 12(12):1109-17. PubMed ID: 21992853
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
    Coleman RL; Handley KF; Burger R; Molin GZD; Stagg R; Sood AK; Moore KN
    Gynecol Oncol; 2020 May; 157(2):386-391. PubMed ID: 32037195
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
    Rose PG; Fusco N; Fluellen L; Rodriguez M
    J Clin Oncol; 1998 Apr; 16(4):1494-7. PubMed ID: 9552057
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q).
    Herzog TJ; Sill MW; Walker JL; O'Malley D; Shahin M; DeGeest K; Weiner SA; Mutch D; DeBernardo RL; Lentz SS
    Gynecol Oncol; 2011 Mar; 120(3):454-8. PubMed ID: 21168198
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.
    Morgan MA; Darcy KM; Rose PG; DeGeest K; Bookman MA; Aikins JK; Sill MW; Mannel RS; Allievi C; Egorin MJ;
    Gynecol Oncol; 2008 Sep; 110(3):329-35. PubMed ID: 18597837
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Suppressive effect upon carboplatin hypersensitivity reaction via pegylated liposomal doxorubicin combination therapy.
    Shimada K; Nagao S; Suzuki K; Shibutani T; Yamamoto K; Jimi T; Yano H; Kitai M; Shiozaki T; Yamaguchi S
    Int J Clin Oncol; 2020 Sep; 25(9):1718-1725. PubMed ID: 32447473
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial.
    Kushner DM; Connor JP; Sanchez F; Volk M; Schink JC; Bailey HH; Harris LS; Stewart SL; Fine J; Hartenbach EM;
    Gynecol Oncol; 2007 May; 105(2):358-64. PubMed ID: 17258800
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
    Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
    Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
    Raja FA; Griffin CL; Qian W; Hirte H; Parmar MK; Swart AM; Ledermann JA
    Br J Cancer; 2011 Sep; 105(7):884-9. PubMed ID: 21878941
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer.
    Brown JV; Peters WA; Rettenmaier MA; Graham CL; Smith MR; Drescher CW; Micha JP
    Gynecol Oncol; 2003 Feb; 88(2):136-40. PubMed ID: 12586592
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.
    Vasey PA; Gore M; Wilson R; Rustin G; Gabra H; Guastalla JP; Lauraine EP; Paul J; Carty K; Kaye S;
    Br J Cancer; 2008 Jun; 98(11):1774-80. PubMed ID: 18506181
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
    Kristeleit R; Davidenko I; Shirinkin V; El-Khouly F; Bondarenko I; Goodheart MJ; Gorbunova V; Penning CA; Shi JG; Liu X; Newton RC; Zhao Y; Maleski J; Leopold L; Schilder RJ
    Gynecol Oncol; 2017 Sep; 146(3):484-490. PubMed ID: 28698009
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer.
    Taylor SE; Petschauer JS; Donovan H; Schorzman A; Razo J; Zamboni WC; Edwards RP; Zorn KK
    Int J Gynecol Cancer; 2019 Jan; 29(1):147-152. PubMed ID: 30640697
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients.
    Becker DA; Leath CA; Walters-Haygood CL; Smith BQ; Bevis KS
    Am J Clin Oncol; 2019 Jan; 42(1):12-16. PubMed ID: 29782365
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma.
    Rose PG; Smrekar M; Haba P; Visser C; Beeler JF
    Gynecol Oncol; 2005 Dec; 99(3):714-9. PubMed ID: 16112177
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
    Sabbatini P; Aghajanian C; Dizon D; Anderson S; Dupont J; Brown JV; Peters WA; Jacobs A; Mehdi A; Rivkin S; Eisenfeld AJ; Spriggs D
    J Clin Oncol; 2004 Nov; 22(22):4523-31. PubMed ID: 15542803
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer.
    Micha JP; Goldstein BH; Rettenmaier MA; Genesen M; Graham C; Bader K; Lopez KL; Nickle M; Brown JV
    Int J Gynecol Cancer; 2007; 17(4):771-6. PubMed ID: 17343605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.